

# Fatima Dubois

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2944923/publications.pdf>

Version: 2024-02-01

17  
papers

420  
citations

840776

11  
h-index

888059

17  
g-index

20  
all docs

20  
docs citations

20  
times ranked

717  
citing authors

#	ARTICLE	IF	CITATIONS
1	RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non-“Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway. <i>Cancer Research</i> , 2016, 76, 1627-1640.	0.9	92
2	High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non-“Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1203-1213.	4.1	77
3	RASSF1A, puppeteer of cellular homeostasis, fights tumorigenesis, and metastasis-“an updated review. <i>Cell Death and Disease</i> , 2019, 10, 928.	6.3	51
4	Hic-5 expression is a major indicator of cancer cell morphology, migration, and plasticity in three-dimensional matrices. <i>Molecular Biology of the Cell</i> , 2018, 29, 1704-1717.	2.1	33
5	A role for RASSF1A in tunneling nanotube formation between cells through GEFH1/Rab11 pathway control. <i>Cell Communication and Signaling</i> , 2018, 16, 66.	6.5	28
6	Paxillin regulates cell polarization and anterograde vesicle trafficking during cell migration. <i>Molecular Biology of the Cell</i> , 2017, 28, 3815-3831.	2.1	26
7	Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy. <i>European Respiratory Review</i> , 2013, 22, 565-576.	7.1	23
8	NDR2 kinase contributes to cell invasion and cytokinesis defects induced by the inactivation of RASSF1A tumor-suppressor gene in lung cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 158.	8.6	22
9	Investigating Tunneling Nanotubes in Cancer Cells: Guidelines for Structural and Functional Studies through Cell Imaging. <i>BioMed Research International</i> , 2020, 2020, 1-16.	1.9	21
10	MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial. <i>Oncotarget</i> , 2017, 8, 4313-4329.	1.8	16
11	Cancer and RASSF1A/RASSF1C, the Two Faces of Janus. <i>Trends in Cancer</i> , 2019, 5, 662-665.	7.4	14
12	Centrosome, the Newly Identified Passenger through Tunneling Nanotubes, Increases Binucleation and Proliferation Marker in Receiving Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9680.	4.1	5
13	Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial. <i>Cancers</i> , 2019, 11, 1835.	3.7	4
14	Optimization of Advanced Live-Cell Imaging through Red/Near-Infrared Dye Labeling and Fluorescence Lifetime-Based Strategies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11092.	4.1	4
15	Deciphering Promoter Hypermethylation of Genes Encoding for RASSF/Hippo Pathway Reveals the Poor Prognostic Factor of RASSF2 Gene Silencing in Colon Cancers. <i>Cancers</i> , 2021, 13, 5957.	3.7	2
16	A defect of amphiregulin release predicted longer survival independently of <sc>YAP</sc> expression in patients with pleural mesothelioma in the <sc>IFCT</sc> -0701 <sc>MAPS</sc> phase 3 trial. <i>International Journal of Cancer</i> , 2022, 150, 1889-1904.	5.1	1
17	The Use of Pro-Angiogenic and/or Pro-Hypoxic miRNAs as Tools to Monitor Patients with Diffuse Gliomas. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6042.	4.1	1